

TIMELINE

Recruitment

60 patients from primary care that
fulfil selection criteria.
Signing of informed consent

Randomisation

Memantine Group (n=30)

Placebo Group (n=30)

Initial assessment

1st visit (baseline assessment). Evaluation of study
variables (neuroimaging tests and administration
of questionnaires)
Administration of memantine/placebo

1st month

Progressive increase of the dose to a daily intake of
20 mg of memantine/placebo.
2nd visit (1 month assessment): administration of
questionnaires.

3rd month

Dose of 20mg of memantine/placebo
3rd visit (3 month assesment). Evaluation of study
variables (administration of questionnaires)

6th month

Dose of 20mg of memantine/placebo.
4th visit (6 month assessment). Evaluation of
variables (neuroimaging tests and questionnaires)